We are a leading company distinguished from typical generic manufacturers, specializing in the development of Incrementally Modified Drugs with a focus on advanced formulation technologies and drug delivery systems. Our R&D division actively responds to rapid changes in both domestic and global markets, striving to develop effective new types of medicines, primarily for diabetes, high cholesterol, and others. We leverage our proprietary technologies and extensive know-how to produce competitive and high-quality medical products, adhering strictly to GMP standards. Our manufacturing facilities have been verified by international audits, including those from Japan's PMDA, Russia & EAEU, demonstrating our global export capabilities to more than ten countries.
more >
Year of Establishment:
1953
Total Assets(USD):
More than 99,999,999
Total Number of Staff:
500-1000
Main Competitive Advantages:
International Approvals/Standards,Experienced R&D Staff
Other Competitive Advantages:
Patents and Copyrights:
Business Type:
Manufacturer
R&D capacity:
OEM,Own Brand
Annual Turnover(USD):
More than 99,999,999
Main Sales Markets:
Central/South America,Asia,Middle East
Other Competitive Advantages:
Patents and Copyrights: